Company / Cash & Equivalents
Cardiff Oncology, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$17.5M
FY2025
5-year range
$11.9M / $51.5M
FY2021-FY2025
Trend
-66.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $8M in FY2018 to $131M in FY2020.
Based on SEC 10-K filings.
$17M in FY2025 with a 5-year CAGR of -33.2%.
Declined from $22M to $17M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +2.2%
- 5-Year CAGR
- -33.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -33.2%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 66.1% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
- Lowest cash & equivalents in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.5M | -66.1% |
| FY2024 | $51.5M | +137.7% |
| FY2023 | $21.7M | +32.5% |
| FY2022 | $16.3M | +36.9% |
| FY2021 | $11.9M | -90.9% |
| FY2020 | $131.0M | +1184.7% |
| FY2019 | $10.2M | +23.9% |
| FY2018 | $8.2M | -40.9% |
| FY2017 | $13.9M | -49.0% |
| FY2016 | $27.3M | -59.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026